A-Portfolio

The company in one breath

Byrna Technologies, ticker BYRN on the Nasdaq Capital Market, sells carbon-dioxide-powered launchers that fire impact or chemical-irritant rounds for people who want self-defense without carrying a firearm.

Consumers buy launchers, projectiles, sprays, alarms, and accessories online, through Amazon (AMZN), in company stores, and from dealers. Police and security buyers add a smaller professional market. The repeat-purchase angle sits in projectiles and carbon-dioxide cartridges. Good would look like launcher sales creating years of refill demand, not one expensive gadget gathering dust beside the treadmill.

Why now

The stock closed at $4.73 on October 8, up 16.8% that day. That means buyers cheered a turnaround plan even though quarterly sales collapsed. Good would look like the next report validating that enthusiasm with actual growth, because applause is not revenue.

The latest quarter was ugly, but the pieces of a repair job showed up. Byrna outsourced ammunition production, rebuilt its marketing, bought HERO Defense Systems (private), and hired new retail and brand leaders. Management says website traffic reached more than 29,000 sessions a day in August, the highest since March. That means more shoppers reached the front door. Good would look like at least 0.8% of those visits becoming purchases soon, on the way toward management's 1% goal.

The share price matters. At $4.73, the whole company costs about $110.7 million in the stock market. Subtract $9.4 million of cash and marketable securities and the operating business costs roughly $101.3 million. That equals about 1.1 times the last twelve months of sales, meaning investors pay close to one dollar for each dollar of recent revenue. Good would look cheap below 1 time sales, but only if sales stop falling and cash stops leaking.

The numbers, translated

• Quarterly revenue was $15.3 million, down 45.7%. Revenue is the money customers paid before expenses. Good for a small consumer brand would look like growth above 15%, so this missed the bar by a zip code.
• Nine-month revenue was $60.7 million, down 26.7%. That means the weakness lasted longer than one bad quarter. Good would look like the next two quarters growing from the immediately previous quarter, then returning to year-over-year growth.
• Adjusted gross margin was 64.5%. Gross margin is what Byrna kept from each sales dollar after making the product, before marketing, payroll, and overhead. It kept about 65 cents, which is strong for hardware. Good would look above 63 cents without tariff refunds or accounting cleanup doing the lifting.
• The standard-accounting net loss was $2.9 million, or 19 cents lost per revenue dollar. That means healthy product margins could not cover the rest of the company. Good would look like a net loss below 5 cents per revenue dollar, then profit.
• Operating cash burn was $3.5 million over nine months. Operating cash shows what normal business activity added to or removed from the bank. Good would look positive over a full year, because a turnaround funded by a shrinking cash pile has a timer attached.
• Cash and marketable securities totaled $9.4 million, with no borrowings outstanding. That means lenders are not standing on the company's throat today. Good would look above $10 million while operations generate cash, not after a stock sale.
• Inventory was $30.0 million, equal to 65.5% of current assets. Inventory is product waiting to sell, and almost two-thirds of Byrna's near-term resources sit on shelves. Good would look below $27 million next quarter, matching management's plan to cut it by $2 million to $3 million.
• The current ratio was 5.5. That means Byrna had about $5.50 of near-term assets for every $1 of near-term bills. Good would normally look above 2, so short-term bill coverage looks comfortable, but most of that cushion is inventory rather than cash.
• Shares outstanding grew 3.2% in nine months. More shares make each old share own a smaller slice. Good would look below 2% annual growth, unless new shares buy something that clearly adds more value than they dilute.

What I like

The product owns a clean sentence: stopping power without a firearm. That is easy to understand, emotionally powerful, and broad enough to reach gun owners and people who refuse to own a gun. A company that creates the category can become the word customers use for it. Good would look like unaided brand awareness rising while customer-acquisition cost falls.

The manufacturing change has teeth. Outsourcing ammunition improved that product's gross margin by about 12 percentage points. That means Byrna kept roughly 12 cents more from each ammunition sales dollar than before. Good would look like that gain surviving for several quarters while quality and delivery stay clean.

The balance sheet has no funded debt, and current assets comfortably cover current bills. That gives the new chief executive room to fix demand without a banker calling every morning. Good would look like the company using that room to sell inventory, not to buy another turnaround before finishing this one.

HERO cost little upfront and adds smaller products and new price points. Good would look like the January relaunch lifting total sales without stealing demand from Byrna's existing lineup. A cheap acquisition can be smart. It can also be a garage sale with nicer slides.

What worries me

Sales did not stumble. They fell down the stairs. A 45.7% quarterly decline and a 26.7% nine-month decline say last year's demand, advertising, and retail restocking did not repeat. Good would look like sequential growth immediately, because another quarter near $15 million would turn “transition” into corporate perfume.

Inventory dwarfs cash. Byrna has $30.0 million of product and only $9.4 million of cash and marketable securities. That means the turnaround depends on converting boxes into dollars without desperate discounts. Good would look like inventory falling while adjusted gross margin stays above 63%.

The company recorded $1.7 million of bad-debt and other one-time costs tied partly to international customers. That means some reported sales did not become collectible cash. Good would look like no new large customer reserve and tighter payment terms abroad.

The filing also disclosed that certain Fox Labs sprays used a solvent prohibited for consumer use under federal rules. Byrna stopped shipments and reported the issue to regulators. I do not know the final cost. Good would look like a quick reformulation, a small write-off, no recall spiral, and no damage to the broader brand.

The crowd offers almost no independent proof. Thirty-day research found two company-specific Reddit posts with one upvote each, while YouTube, Hacker News, GitHub, and prediction markets produced nothing useful. Good would look like real customers and dealers discussing repeat use, product reliability, and retail sell-through. Silence is not a scandal. It is not a moat either.

What would make this a buy

My research threshold starts with proof, not hope. I want quarterly revenue above $20 million, which would mean sales grew at least 31% from the latest quarter. I want adjusted gross margin above 63%, which would show the factory improvement survived without the one-time tariff refund. I want positive quarterly operating cash flow, which would mean the repair job funds itself.

I also want inventory below $27 million, website conversion above 0.8%, and no material penalty from the spray issue. Good would look like all of that arriving together.

Price still matters. At $4.00, the operating business would cost about $84 million, or roughly 0.9 times recent sales after subtracting current cash. That gives more room for another weak quarter. At $4.73, I need the operating proof first. Cheap plus broken is not value. It is a repair estimate.

What makes me walk away

I walk if quarterly revenue stays below $16 million for another quarter. That would mean the new marketing engine failed to create meaningful demand.

I walk if adjusted gross margin falls below 60% while inventory stays above $30 million. That combination would mean Byrna must discount product and lose the margin edge at the same time.

I walk if cash and marketable securities fall below $6 million before operating cash turns positive. That would leave too little room for mistakes and raise the odds of new shares or debt.

I also walk if regulators force a broad recall, if another international customer stops paying, or if share growth exceeds 8% before profitability returns. A turnaround should repair the business, not transfer it from old owners to new ones.

IPO Watch

• TRex Bio, private, proposed ticker TRXB, expected October 9 at a final price of $14. It develops drugs that tune immune-regulating cells for inflammatory disease. I would write it up when early human data shows its lead drug changes disease biology safely, because a platform with no clinical proof is still a PowerPoint wearing a lab coat.
• Retension Pharmaceuticals, private, proposed ticker RTSN, expected October 9 at a final price of $12. It develops a once-daily pill for blood pressure that existing drugs do not control. I would write it up when the cash runway clearly reaches the expected 2027 mid-stage trial result without another stock sale.
• Iambic Therapeutics, private, proposed ticker IAM, expected October 15 at $15 to $17. It combines artificial intelligence with automated lab work to design cancer drugs. I would write it up when the final valuation leaves room for clinical failure and the lead drug produces convincing human tumor data.

Earnings On Deck

• BYRN, reported October 8. Revenue fell to $15.3 million, but adjusted gross margin rose to 64.5% and the stock gained 16.8%. A good follow-through means holiday sales cut inventory by $2 million to $3 million and produce positive cash. A bad one means the market celebrated cost cuts while customers kept walking past the shelf.

The verdict

Score: 58 out of 100. Bucket: pass. Byrna earned points for a distinct category, strong product-level margins, no funded debt, a cheap sales multiple, manufacturing improvement, new leadership, and clear near-term tests.

It lost far more for collapsing sales, renewed losses, cash burn, inventory equal to almost two-thirds of current assets, customer-credit trouble, regulatory risk, share growth, and almost no independent community proof. A watch starts at 65. Byrna misses by seven. The turnaround has a pulse. It does not have a clean bill of health.

The DBTech read

Working capital is the cash trapped between buying inventory and collecting from customers. Byrna has $30.0 million sitting in products but only $9.4 million in cash and marketable securities. Selling those products near full price releases cash, while discounting or writing them off destroys value. Good working capital turns shelves into bank deposits quickly. A packed pantry is useful only if dinner guests actually show up.

Sources and as-of date

• Price: $4.73 at 4:00 p.m. Eastern on October 8, 2026, the latest completed regular-session close, and $4.79 at 4:20 a.m. Eastern on October 9, 2026, the latest available premarket indication, Yahoo Finance. Retrieved at 7:04 a.m. Eastern on October 9, 2026. Every valuation uses the liquid $4.73 close.
• Robinhood verification: Robinhood (HOOD) still displayed the October 7 session on its public page when checked, and the read-only Robinhood MCP quote and chain tools were not available in this run. I used Yahoo Finance for the live timestamp and MarketBeat only to confirm that listed options exist. No fill, bid, ask, or Greek enters this issue.
• Business, financial statements, cash flow, inventory, share count, HERO acquisition, credit facilities, spray regulation, and risks: Byrna fiscal third-quarter Form 10-Q, filed October 8, 2026.
• Quarterly results, margins, creator network, leadership changes, and management commentary: Byrna fiscal third-quarter release, published October 8, 2026.
• Website conversion, creator-program sales, inventory target, HERO timing, and retail commentary: fiscal third-quarter earnings-call transcript, retrieved October 9, 2026.
• Leadership and governance: Byrna 2026 proxy statement, filed September 2, 2026.
• Current product positioning: Byrna product site, retrieved October 9, 2026. Good research uses the company's pitch to understand the product, not to certify its claims.
• IPO dates and terms: IPO Scoop calendar, Retension pricing release, and Iambic registration statement, retrieved October 9, 2026. Expected dates can move until trading begins.
• Community research covered September 9 through October 9, 2026. The focused evidence found 25 Reddit threads, but only two were company-specific and each had one upvote. The engine returned no usable YouTube, Hacker News, GitHub, or prediction-market evidence. Raw research: workspace/newsletters/a-portfolio/research/byrna-technologies-byrn-turnaround-raw-v3.md.
• Calculations use decimal arithmetic, the $4.73 close, 23,404,754 shares, $9.419 million of cash and marketable securities, $95.979 million of trailing revenue, and the latest filed balance sheet. Research and commentary only, never a buy signal.